XLO — Xilio Therapeutics Balance Sheet
0.000.00%
- $38.84m
- -$16.45m
- $6.34m
Annual balance sheet for Xilio Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Cash and Short Term Investments | 19.2 | 198 | 120 | 44.7 | 55.3 |
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 20.6 | 203 | 124 | 48.1 | 60.2 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 13.7 | 13.9 | 13.1 | 11.2 | 9.06 |
Other Long Term Assets | |||||
Total Assets | 36.3 | 218 | 139 | 60.9 | 71.1 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 22.2 | 12.8 | 21.1 | 16 | 27.3 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 41.6 | 32.6 | 33.5 | 24.1 | 53.5 |
Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | -5.29 | 185 | 106 | 36.8 | 17.6 |
Total Liabilities & Shareholders' Equity | 36.3 | 218 | 139 | 60.9 | 71.1 |
Total Common Shares Outstanding |